Guardant Health, Inc. $GH Stock Holdings Lowered by Sicart Associates LLC

Sicart Associates LLC reduced its position in Guardant Health, Inc. (NASDAQ:GH) by 21.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 181,030 shares of the company’s stock after selling 49,985 shares during the quarter. Guardant Health comprises approximately 7.7% of Sicart Associates LLC’s investment portfolio, making the stock its 2nd largest position. Sicart Associates LLC’s holdings in Guardant Health were worth $32,289,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Financial Network Wealth Advisors LLC lifted its position in Guardant Health by 17.2% in the third quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock valued at $75,000 after buying an additional 62 shares during the last quarter. Yousif Capital Management LLC boosted its stake in shares of Guardant Health by 6.2% in the third quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock valued at $283,000 after purchasing an additional 93 shares during the period. Allworth Financial LP grew its holdings in shares of Guardant Health by 12.4% in the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after purchasing an additional 118 shares in the last quarter. GAMMA Investing LLC increased its stake in Guardant Health by 14.5% during the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after buying an additional 122 shares during the period. Finally, Slow Capital Inc. increased its stake in Guardant Health by 0.3% during the 3rd quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock worth $9,397,000 after buying an additional 136 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on GH shares. Stephens upped their price target on Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. upped their price objective on Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Roth Capital began coverage on Guardant Health in a report on Thursday, October 22nd. They issued a “buy” rating and a $200.00 price objective on the stock. Morgan Stanley boosted their target price on Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Bank of America increased their price target on shares of Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

Insider Transactions at Guardant Health

In other news, CEO Amirali Talasaz sold 37,500 shares of Guardant Health stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the completion of the transaction, the chief executive officer owned 37,500 shares of the company’s stock, valued at $6,343,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Steve E. Krognes sold 6,674 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total value of $1,172,888.76. Following the completion of the sale, the director directly owned 7,906 shares in the company, valued at approximately $1,389,400.44. The trade was a 45.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 178,940 shares of company stock valued at $30,070,911. 5.60% of the stock is owned by company insiders.

Guardant Health Stock Performance

NASDAQ GH opened at $178.80 on Monday. Guardant Health, Inc. has a one year low of $74.55 and a one year high of $191.05. The firm’s fifty day moving average is $169.71 and its two-hundred day moving average is $130.68. The firm has a market cap of $23.99 billion, a PE ratio of -51.23 and a beta of 1.67.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million for the quarter, compared to analysts’ expectations of $314.23 million. Guardant Health’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.44) EPS. Research analysts predict that Guardant Health, Inc. will post -3.08 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.